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Background: Performance measures are used for assessing quality
of care. Higher performance shown by these measures is expected
to reﬂect better care, but little is known whether they predict better
patient outcomes.
Objective: To assess the predictive value of performance measures
of glucose management on glycemic control, and evaluate the im-
pact of patient characteristics on this association.
Research Design: Cohort study (2007–2009).
Subjects: A total of 15,454 type 2 diabetes patients (mean age,
66.5y; 48% male) from the GIANTT cohort.
Measures: We included performance measures assessing frequency
of HbA1c monitoring, glucose-lowering treatment status, and
treatment intensiﬁcation. Associations between performance and
glycemic control were tested using multivariate linear regression
adjusted for confounding, reporting estimated differences in HbA1c
with 95% conﬁdence intervals (CI). Impact of patient characteristics
was examined through interactions.
Results: Annual HbA1c monitoring was associated with better
glycemic control when compared with no such monitoring (HbA1c
0.29%; 95% CI 0.37, 0.22). This association lost signiﬁcance
in patients with lower baseline HbA1c, older age, and without
macrovascular comorbidity. Treatment status was associated with
better glycemic control only in patients with elevated baseline
HbA1c. Treatment intensiﬁcation after elevated HbA1c levels was
associated with better glycemic control compared with no in-
tensiﬁcation (HbA1c 0.21; 95% CI 0.26, 0.16).
Conclusions: Performance measures of annual HbA1c monitoring
and of treatment intensiﬁcation did predict better patient outcomes,
whereas the measure of treatment status did not. Predictive value of
annual monitoring and of treatment status varied across patient
characteristics, and it should be used with caution when patient
characteristics cannot be taken into account.
Key Words: quality of care, quality assessment, performance
measurement, diabetes
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A
dequate blood glucose management is considered essen-
tial for diabetes care to prevent long-term complica-
tions.1,2 Performance measures have been developed to assess
whether patients are receiving the recommended care.3–6 They
are used by policy makers for pay for performance and by
health care providers for quality improvement.7,8 Currently,
there is an ongoing debate on the development of new or
improved diabetes performance measures.9 An important re-
quirement for measuring performance is credible evidence
linking higher performance estimates to better patient out-
comes.9–11 For comparing practices, the measures should not
be sensitive to common variations in patient populations.
Variation in sociodemographics and clinical characteristics can
inﬂuence diabetes performance and outcomes,10–14 but there is
limited knowledge about how these variations affect the utility
of speciﬁc performance measures.15
Commonly used measures for glucose management as-
sess simple care processes in the diabetes population: whether
HbA1c is tested,3,16 or whether diabetes patients are being
treated with glucose-lowering drugs.3,5 The rationale behind
these measurements is based on recommendations found in
guidelines stipulating that all diabetes patients need regular
monitoring and that most need medication treatment. The as-
sociation between HbA1c monitoring and glycemic control has
been tested,17–20 but the results are inconclusive.21
As these measures include all diabetes patients in the
denominator, variations in the study population may inﬂu-
ence the outcomes. There is no consensus on the recom-
mended frequency of testing.22 More frequent monitoring is
recommended in uncontrolled patients.2 Therefore, the utility
of this performance measure may be limited to such patients.
Evidence linking performance measures of current
treatment with patient outcomes is lacking.21 In recent years,
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more meaningful performance measures.9,15,23 They measure
clinical action by assessing whether medication has been
started or intensiﬁed in patients with elevated HbA1c levels.
These measurements have shown positive associations with
better glycemic control in longitudinal studies.24–28 Never-
theless, there is debate concerning the HbA1c thresholds used
in these.9,29 The objective of our study is to evaluate the utility
of the various performance measures of glucose management
to predict glycemic control and to understand the extent to
which this depends on patient characteristics.
METHODS
An observational cohort study was conducted using
data from 2007 to 2009, including patients with type 2 dia-
betes registered in 150 general practices (GPs) in the prov-
ince of Groningen, The Netherlands. All patients with
diabetes diagnosed before January 1, 2008, and managed by
the GP were included. Around 85% of Dutch diabetes pa-
tients are managed by the GP. Dutch patients irrespective of
their socioeconomic status have a mandatory basic insurance
allowing for primary diabetes care without restrictions. The
population in the Groningen region consisted in 2008 of 89%
individuals of West European origin, with an average gross
income of h25,500 (US$B38,250).
The data were collected from the Groningen Initiative
to Analyze Type 2 diabetes Treatment (GIANTT) database.
This longitudinal database contains anonymous data from
electronic medical records, including full prescription data,
comorbidity and event data, routine laboratory test results,
and physical examinations. Data are extracted using vali-
dated, automatic procedures, including semiautomated
quality checks of data used in this study.30 Prescription data
include information on the drugs’ dosages, daily use, and
prescribed quantity, enabling the assessment of dosage in-
creases and decreases, as well as switches between drugs.
Comorbidity and major clinical events are documented on
“problem lists” in the medical records. These consist of the
International Classiﬁcation of Primary Care (ICPC) codes31
or short text descriptions, which were coded to ICPC or a
separate code for conditions not covered, such as left ven-
tricular hypertrophy or bypass grafting.
In The Netherlands, according to the Code of Conduct
for the use of data in Health Research (“Gedragscode
gezondheidsonderzoek” approved in 2004 by the Dutch
College for Protection of Personal Data, taking into account
Article 25 of the Dutch Act on the Protection of Personal
Data) no ethics committee approval was required for this
research using data from anonymous medical records.
Performance Measures Linked to Glycemic
Control
We included commonly used or suggested perform-
ance measures of glucose management, which assess quality
of the following processes of care: (1) HbA1c monitoring
(monitoring); (2) current status of glucose-lowering treat-
ment (treatment status); and (3) glucose-lowering treatment
intensiﬁcation when indicated (treatment intensiﬁcation). We
evaluated clinical performance for the year 2008.
To test the predictive value of “monitoring”, we as-
sessed (a) whether undergoing at least 1 HbA1c test in the
year 2008 was associated with better glycemic control
compared with no tests, and (b) whether undergoing 2 or
more HbA1c tests resulted in better glycemic control com-
pared with a single test. Only patients having a baseline
HbA1c in 2007 and an outcome HbA1c in 2009 were
included for this assessment (Table 1).
To test the predictive value of “treatment status,” we
assessed whether being on any glucose-lowering treatment was
associated with better glycemic control compared with the
absence of such treatment. A patient was considered as being
on treatment when a prescription or reﬁll for a glucose-low-
ering drug was recorded within the last 3 months of 2008.5
To test the predictive value of “treatment in-
tensiﬁcation,” we assessed whether receiving glucose-regulat-
ing treatment intensiﬁcation after an elevated HbA1c was
associated with better glycemic control compared with no in-
tensiﬁcation. Similarly, we assessed this association for treat-
ment intensiﬁcation in patients having 2 repeatedly elevated
HbA1c values, as doctors may wait for a conﬁrmation test
before acting. An HbA1c>7% was used as primary threshold
in accordance with the Dutch guideline.2 As higher threshold
levels for performance measures have been suggested to allow
for patients not in need of strict control,15,24–26 we also eval-
uated these measures of “treatment intensiﬁcation” using a
threshold HbA1c>8.5% that is considered to constitute poor
control for most patients in primary care. Treatment in-
tensiﬁcation was deﬁned as the start or addition of a new drug
class or a dosage increase occurring within 120 days after an
elevated HbA1c. The time period of 120 days takes into ac-
count possible delays until the next regular visit because of
competing demands or clinical uncertainty.32,33 Switches from
one drug to another or dosage increases coinciding with dosage
decreases within a 7-day time window were not classiﬁed as
treatment intensiﬁcation. However, a switch to insulin was
always considered intensiﬁcation. Patients already on insulin at
baseline were excluded from the intensiﬁcation measurements,
because intensiﬁcation of insulin regimen cannot be reliably
estimated from available prescription data. Drug classes in-
cluded were: biguanides, sulfonylureas, a-glucosidase in-
hibitors, thiazolidinediones, dipeptidyl-peptidase-4-inhibitors,
insulins, and other blood glucose–lowering drugs.
Glycemic Control Outcome
Glycemic control was deﬁned by means of the HbA1c
values recorded at baseline and after the care process as-
sessed by each performance measure. For “HbA1c mon-
itoring,” the outcome was the ﬁrst HbA1c value in 2009. For
“treatment status” and “treatment intensiﬁcation,” the out-
come was the ﬁrst HbA1c value within a period of 21–120
days after the prescription date of the treatment or treatment
intensification. This is the period in which an effect from the
treatment can be expected.33 For patients without glucose-
lowering treatment or treatment intensification, glycemic
control was assessed similarly after a random date drawn
from the observed distribution of prescription dates in
patients with glucose-lowering treatment or treatment
intensification.
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As the likelihood of receiving care may depend on
patient characteristics, which could partly explain differ-
ences in HbA1c levels, we adjusted for possible confounders.
In addition, we evaluated whether patient characteristics
modiﬁed the effect of performance measures on the HbA1c
outcome. We included the following characteristics as pos-
sible confounders and effect modiﬁers13,34–36: (1) age, sex,
and diabetes duration; and (2) comorbidity, including (a)
diabetes-related macrovascular comorbidity, (b) diabetes-
related microvascular comorbidity, and (c) mental co-
morbidity. Macrovascular comorbidity included: transient
cerebral ischemia (ICPC-code K89),31 heart failure (K77),
stroke (K90), atherosclerosis (K91), myocardial infarction
(K75 and K76), angina (K74), coronary artery bypass
grafting, percutaneous transluminal coronary angioplasty,
and left ventricular hypertrophy. Microvascular comorbidity
included: diabetes neuropathy (N94.2), retinopathy (F83),
renal failure (U99.1), renal hyperplasia/hydronephrosis
(U99.2 and U99.3), terminal dialysis, kidney transplantation,
diabetes foot, and related amputations. Mental comorbidity
was identiﬁed by the codes for psychological disorders
ranging from dementia (P70) to other psychological dis-
orders (P99).31 Comorbidity was scored as the presence or
absence in the preceding 10 years.
Statistical Analysis
We used descriptive statistics and independent t tests to
compare groups at baseline. We assessed the predictive value
of each of the performance measures on glycemic control in
separate analyses adjusting for confounding. We conducted
multilevel linear regression with random intercept to esti-
mate the impact of the GP cluster level on the associations
between the performance measures and glycemic control.
The proportion of variance that was accounted for by the GP
level was calculated for each model through intraclass cor-
relation coefﬁcients (ICCs). As the ICC was <0.01 for all the
tested associations, we present our results at patient level
using multivariate linear regression models.
The relationship between performance measures and
glycemic control was investigated by evaluating the effect
sizes (b), reﬂecting the estimated differences in outcome
HbA1c levels for patients with or without the recommended
care. Effect modiﬁcation was examined by evaluating in-
teractions between the performance measure and the baseline
patient characteristics in the fully adjusted models.
Sensitivity Analyses
We conducted additional analyses using an HbA1c
outcome assessment period of 180 days instead of 120 days
to test whether the associations might be biased by restricting
them to patients with available HbA1c test within 120 days.
A second set of sensitivity analyses concerned adjust-
ment for other possible confounders in a subset of patients
with available additional data, including systolic blood
pressure (SBP), low-density lipoprotein cholesterol (LDL-
C), and body mass index (BMI). We also conducted addi-
tional analyses adjusting on an overall comorbidity score
instead of the selected comorbidity clusters. For this, we used
the modiﬁed Charlson comorbidity score37 on the basis of
the ICPC codes (see Table, Supplemental Digital Content 1,
http://links.lww.com/MLR/A391, which illustrates scoring
the Charlson comorbidity from the ICPC codes).
RESULTS
A total of 15,454 patients with a type 2 diabetes di-
agnosis before 2008 were eligible for the study. Baseline
characteristics are shown in Table 2. The numbers of patients
included were in the range from 406 for “treatment in-
tensiﬁcation” in patients with 2 sequential HbA1c>8.5% to
TABLE 1. Definition of Performance Measures and Related Baseline and Outcome Measurements, With Numbers of Patients
Included; in Total, 15,454 Diabetes Patients are Included in the Study Population
Performance Measures (No. Patients
Eligible for Inclusion) Baseline Measurement
Deﬁnition of
Performance
Glycemic Control
Outcome
Diabetes patients who received HbA1c test(s) in the
measurement period (n=12,826 who had baseline test
in 2007)
Last HbA1c test in 2007
Z1 vs. 0 tests
Z2 vs. 1 tests in 2008
First HbA1c test in 2009
(n=11,844)
(n=11,353)
Diabetes patients who are treated with glucose-lowering
drugs (n=13,582 who had a baseline test in 2008)
First HbA1c test in 2008 Glucose-lowering drug
prescription within last
3mo of 2008
First HbA1c test in a period
of 21–120d after the drug
prescription date
(n=8921)
Diabetes patients not on insulin with HbA1c>7% receiving
glucose-lowering treatment intensiﬁcation (n=5189 of
the 13,582 who had a test in 2008)
First HbA1c test in 2008,
if >7%
Glucose-lowering drug start
or dosage increase within
120d after baseline test
First HbA1c test in a period
of 21–120d after date of
intensification (n=3620)
Diabetes patients not on insulin with HbA1c>8.5%
receiving glucose-lowering treatment intensiﬁcation
(n=875 of the 13,582 who had a test in 2008)
First HbA1c test in 2008,
if >8.5%
First HbA1c test in a period
of 21–120d after date of
intensification (n=550)
Diabetes patients not on insulin with 2 sequential
HbA1c>7% receiving glucose-lowering treatment
intensiﬁcation (n=3623 of the 10,413 who had at least 2
tests in 2008)
First HbA1c test >7% in
2008
Glucose-lowering drug start
or dosage increase within
120d after baseline test
First HbA1c test in a period
of 21–120d after date of
intensification (n=3027)
Diabetes patients not on insulin with 2 sequential
HbA1c>8.5% receiving glucose-lowering treatment
intensiﬁcation (n=515 of the 10,413 who had at least
2 tests in 2009)
First HbA1c test >8.5% in
2008
First HbA1c test in a period
of 21–120d after date of
intensification (n=406)
Sidorenkov et al Medical Care  Volume 51, Number 2, February 2013
174 | www.lww-medicalcare.com r 2012 Lippincott Williams & Wilkins11,844 for “HbA1c monitoring” in all patients with diabetes
(Table 1). For the 2 “monitoring” measures, 12% of patients
were excluded for having no baseline HbA1c test in 2007.
For 3 of the treatment measures, 17% of patients were ex-
cluded for having no baseline HbA1c test in 2008. For
“treatment intensiﬁcation” after sequential tests, 33% of
patients were excluded for not undergoing 2 tests in 2008. In
addition, between 8% and 34% of patients were lost because
of unavailable follow-up outcome tests within the predeﬁned
time periods. Patients without HbA1c tests in 2007–2009 had
in some cases slightly higher baseline risk factor levels (see
Table, Supplemental Digital Content 2, http://links.lww.com/
MLR/A392), which illustrates the baseline characteristics of
patients depending on the presence/absence of HbA1c test
each year). Mean values of HbA1c at baseline differed in
several cases for patients receiving the care or not receiving
it, as assessed by the performance measures (Table 3).
Association of Performance Measures
and Glycemic Control
Receiving at least 1 HbA1c test compared with no test
in the measurement year was associated with better glycemic
control (Table 3). The tested association was conditioned by
interactions with several patient characteristics (Fig. 1). In
patients with higher baseline HbA1c levels, a stronger as-
sociation was observed between “monitoring” and glycemic
control. With older age, in contrast, the association became
weaker (Fig. 1, top to bottom panels), and even more so for
patients without macrovascular comorbidity (Fig. 1, right
panels). Receiving 2 or more HbA1c tests compared with a
single test was not signiﬁcantly associated with glycemic
control (Table 3). The association was, however, conditioned
by an interaction with the baseline HbA1c level. In patients
with a baseline HbA1c of >7%, undergoing 2 or more
HbA1c tests compared with a single test was signiﬁcantly
associated with achieving better glycemic control (Fig. 2A).
Being on glucose-lowering treatment was not sig-
niﬁcantly associated with glycemic control, but an inter-
action was seen with the baseline HbA1c level. We observed
that being on treatment became signiﬁcantly associated with
better control in patients with higher baseline HbA1c values
(Fig. 2B).
Intensiﬁcation of glucose-lowering treatment in cases
where there was either 1 or 2 sequential HbA1c tests above
7% was associated with better glycemic control (Table 3).
TABLE 2. Patient Characteristics at Baseline in 2008
No. Patients
With Recorded
Observation
Mean±SD
or %
Age (y) 15,454 66.5±12.2
Male sex 7336 47.5
Diabetes duration (y) 15,454 4 [2;8]*
HbA1c (%) 13,582 7.0 (1.0)
Systolic blood pressure (mm Hg) 12,969 143.1±20.3
Total cholesterol (mg/dL) 10,591 179±43
LDL cholesterol (mg/dL) 11,134 97±35
Albumin/creatinine ratio
(mg/mmol)
8735 4.7±14.2
Body mass index 10,099 30.1±5.5
Macrovascular comorbidity
presence
2968 19.2
Microvascular comorbidity
presence
777 5.8
Mental comorbidity presence 784 5.1
*Median [25th and 75th percentiles].
TABLE 3. Numbers of Patients With and Without Recommended Care, Means for Their Baseline Levels and Outcomes, and Effect
Sizes for the Associations Between Performance Measures and Glycemic Control
No. Performance Measures
Total No.
Patients (With/
Without
Recommended
Care)
Mean Baseline
HbA1c (%)
Mean Outcome
HbA1c (%)
Effect Size b
(95% CI) R
2
1 Z1 HbA1c test(s) vs. no test 11,844 (11,353/491) 6.9/6.8* 7.0/7.2 0.29 (0.36, 0.22) 0.27
2 Z2 HbA1c tests vs. 1 test 11,353 (10,140/1213) 6.9/6.7* 7.0/6.9 0.02 (0.07, 0.02) 0.27
3 Treated with glucose-lowering drugs vs.
not treated
8921 (8129/792) 7.1/7.0* 7.1/7.0 0.02 (0.08, 0.03) 0.36
4 Treatment intensiﬁcation vs. no
intensiﬁcation in case of HbA1c>7%
3620 (1113/2507) 7.9/7.9 7.4/7.6 0.18 (0.23, 0.13) 0.38
5 Treatment intensiﬁcation vs. no
intensiﬁcation in case of 2
HbA1c>7%
3027 (895/2132) 8.0/7.9 7.6/7.8 0.19 (0.24, 0.13) 0.33
6 Treatment intensiﬁcation vs. no
intensiﬁcation in case of
HbA1c>8.5%
550 (170/380) 9.6/9.5 8.4/8.6 0.24 (0.46, 0.01) 0.23
7 Treatment intensiﬁcation vs. no
intensiﬁcation in case of 2
HbA1c>8.5%
406 (121/285) 9.8/9.5 8.7/9.1 0.40 (0.64, 0.15) 0.13
*Signiﬁcant baseline differences (independent t test).
b is the estimated differences in HbA1c levels for patients with and without the recommended care, adjusted for age, sex, duration of diabetes, and comorbidity (microvascular,
macrovascular, and mental).
Signiﬁcant associations (linear regression) are indicated in bold.
R
2, coefﬁcient of determination for the fully adjusted model.
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after treatment intensiﬁcation in cases where there were 1 or
2 HbA1c tests above 8.5%. The associations were con-
ditioned by an interaction with the baseline HbA1c level,
showing that in patients with higher baseline levels,
“treatment intensiﬁcation” was associated with a greater
difference in glycemic control (Fig. 2C).
Sensitivity analyses using the extended time period
of 180 days for assessing glycemic control did not change
the ﬁndings of our study. Using the Charlson comorbidity
score to adjust for confounding or including additional risk
factors (SBP, LDL-C, and BMI) as confounders also re-
sulted in almost identical estimates for the studied associa-
tion (see Tables, Supplemental Digital Content 3, http://
links.lww.com/MLR/A393,, which illustrates the sensitivity
analyses).
DISCUSSION
Our study shows that annual HbA1c monitoring
predicts better glycemic control in the overall diabetes
population, whereas more frequent monitoring was only
predictive in insufﬁciently controlled patients. The impact of
annual HbA1c monitoring was inﬂuenced by patient char-
acteristics. When patients were well controlled in combina-
tion with older age and no macrovascular comorbidity,
annual monitoring was not associated with better glycemic
control. Measures of “treatment intensiﬁcation” were
strongly predictive of better glycemic control, whereas this
was not observed for measures of “treatment status.” Such
measures, assessing whether or not patients receive glucose-
regulating treatment, only predicted better glycemic control
in insufﬁciently controlled patients. These ﬁndings imply
that commonly used simple diabetes performance measures
Patients with macrovascular comorbidity
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FIGURE 1. Predictive value of annual HbA1c monitoring (Z1 vs. 0 tests) across varying patient characteristics. The estimated
differences in HbA1c level are presented on the y-axis and increasing baseline HbA1c levels on the x-axis. Panels from top to
bottom show that with increasing age the association becomes nonsignificant for patients with lower baseline HbA1c and from
left to right for patients with or without macrovascular comorbidity.
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used with caution when baseline patient characteristics
cannot be taken into account.
Annual HbA1c monitoring is included in many per-
formance measure sets for diabetes patients,2,3,6,16 yet its im-
pact on improving glycemic control was not conﬁrmed in
previous longitudinal studies.21 Although one would expect a
relationship between annual monitoring and glycemic control,
one should be aware that this will only occur when treatment
of patients with elevated HbA1c level is subsequently im-
proved or when patients with adequate levels deteriorate
without annual monitoring. We observed a stronger predictive
value for annual HbA1c monitoring on glycemic control in
patients with elevated baseline levels. This indicates that more
action is taken in patients with higher HbA1c levels, as has
been observed previously.38 The weaker predictive value of
HbA1c monitoring on glycemic control in older patients with
HbA1c levels below 7%–8% may be explained by considering
a higher threshold for treatment in elderly patients.39 The
stronger predictive value in patients with macrovascular
complications may be explained by more intensive treatment
in such patients. This is in line with a recent finding showing
higher performance rates on processes of care in patients with
more comorbidity.13 Finally, we did not find that more fre-
quent monitoring in 1 year is predictive of glycemic control in
the overall population. More frequent monitoring was, how-
ever, predictive in poorly controlled patients, implying that this
performance measure has more value when used for patients
with elevated HbA1c. In well-controlled patients, in contrast,
less frequent monitoring does not seem to lead to deterioration
in outcomes.
For assessing the quality of treatment, we evaluated a
simple performance measure of “treatment status,” which
assesses whether any glucose-regulating drug treatment is
prescribed in all diabetes patients. This measure is relatively
easy to calculate and is included in the Dutch diabetes per-
formance measure set.5 Our ﬁndings, however, showed no
predictive value for this measure on glycemic control in the
overall population. This may seem surprising but is the result
of including many patients being on treatment who are well
controlled with no (further) improvement in glycemic control
and some who deteriorate because of the lack of treatment
intensiﬁcation. In patients with elevated HbA1c levels,
however, this measure showed its predictive value on better
glycemic control. This implies that stratiﬁcation in meas-
urement and reporting is required when using this perform-
ance measure. The alternative is to restrict the deﬁnition
of this measure to include only diabetes patients with an
elevated HbA1c level, as has been recommended by the
National Quality Forum.4
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FIGURE 2. Predictive value of performance measures of: (A) more frequent HbA1c monitoring, (B) current treatment, and (C)
treatment intensification, across varying baseline HbA1c levels. The estimated differences in HbA1c level are presented on the
y-axis and increasing baseline HbA1c levels on the x-axis. This shows that for more frequent monitoring (A) and current treatment
status (B), the associations become nonsignificant or even negative for patients with low baseline HbA1c. For treatment
intensification, the association becomes stronger in patients with high baseline HbA1c.
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1 step further in the performance measures of “treatment
intensiﬁcation,” which assess whether treatment action is
taken in patients after an elevated HbA1c level. We dem-
onstrated that these performance measures of “treatment
intensiﬁcation” predict better glycemic control. The ob-
served ﬁndings are consistent with previous studies.24–26,28
The estimated difference in glycemic control was greater for
patients with highly elevated HbA1c at baseline. This sup-
ports the view that using higher HbA1c thresholds for per-
formance measures of treatment will better reﬂect clinically
relevant quality of care.9 In contrast, if higher thresholds are
used, fewer patients are eligible for quality assessment.
Strength and Limitations
Our study included a large cohort of primary care
diabetes patients using a fairly unique regional GP database
in The Netherlands. The included population includes mostly
individuals of European ethnicity. Variation on levels of
performance and glycemic control may be larger in countries
where the diabetes population is less well controlled. By
looking at the interaction effects with baseline HbA1c levels
as presented one could infer the expected predicted value of
the performance measures in such populations.
Dutch GPs are obliged to keep adequate medical re-
cords including all diagnostic and prescription data but oc-
casional test results or drugs prescribed by specialists might
be missed. As we included only patients who were managed
by the GP, we do not expect this to be common.
As with any observational research, our study may be
limited by confounding. In our analyses, we adjust for a wide
range of expected confounders. We conducted sensitivity
analysis adjusting for other patient characteristics, which
showed no meaningful differences in the observed associa-
tions but some unmeasured confounding may still be present.
Our study uses HbA1c values as an outcome. Although
HbA1c is considered as a predictor of morbidity and mortal-
ity,40 testing the direct relationship of performance measures to
hard outcomes is required to strengthen the current ﬁndings.
The included population was limited by the need for baseline
and outcome HbA1c values. We did not observe large differ-
ences in demographics, risk factor levels, or comorbidity be-
tween patients with and without HbA1c tests in 2007–2009,
indicating that there was no major selection bias on these pa-
tient characteristics because of this loss of patients. When
extending the period for outcome assessment in our sensitivity
analysis, thereby reducing loss of follow-up, we also observed
no significant changes in our findings.
When assessing “treatment intensiﬁcation,” we ex-
cluded up to 7% of patients already treated with insulin at
baseline. This might lead to an underestimation of the pre-
dictive value of these measures, as insulin is highly effective
at lowering glycemia.
We observed small differences in baseline HbA1c
levels of patients with and without measured performance on
“monitoring” and “treatment status.” Because of differences
in regression toward the mean effects, differences in HbA1c
level of patients receiving the recommended care could be
larger than in those not receiving such care. This implies that
the associations for these performance measures might be
even smaller than observed.
Finally, comorbidity in primary care records could be
incomplete,41 which would result in partial adjustment on
comorbidity. Our comorbidity data were enriched by man-
ually coding text descriptions, resulting in higher co-
morbidity rates compared with that observed in a previous
primary care study conducted in The Netherlands, which was
based on only ICPC-coded comorbidity data.42
Implications
Our study assessed the predictive value of performance
measures of HbA1c monitoring and treatment status on gly-
cemic control in primary care. An important ﬁnding of our
study is that these measures are not equally informative re-
garding the quality of care across patients with different
characteristics. When annual HbA1c monitoring rates are used
for pay for performance or public reporting, adjustment for
baseline HbA1c is recommended. The rates of annual mon-
itoring are not very informative in those patients in whom
monitoring is not expected to lead to changes in treatment, in
particular patients who are already well controlled and elderly.
This implies that it is better to present separate monitoring
rates for patients under and above treatment targets. Further,
when measures are used, which assess whether patients receive
treatment or not, stratiﬁcation is required to differentiate be-
tween well-controlled and poorly-controlled patients. Alter-
natively, one could restrict the deﬁnition of such measures to
include only diabetes patients with an elevated HbA1c. Per-
formance measures of treatment intensiﬁcation incorporate
such restrictions, and these were not sensitive to other differ-
ences in baseline patient characteristics. Such measures can
thus be considered valid instruments in assessing the quality of
glucose management.
CONCLUSIONS
We showed in a large primary care cohort of type 2
diabetes patients that performance measures of annual
HbA1c monitoring and of treatment intensiﬁcation were
predictive of better glycemic control. However, annual
monitoring was affected by differences in patient charac-
teristics. The performance measure of treatment status was
not predictive of better outcomes in general, but it showed
predictive value in patients with elevated HbA1c levels.
Performance measures of annual HbA1c “monitoring” and
of “treatment status” are therefore more meaningful when
restricted to patients with elevated HbA1c level.
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